Introduction
============

Autoimmunity drives the development of multiple sclerosis (MS), involving central nervous system (CNS) infiltration of immune cells, myelin degradation, reactive changes in glia and axonal loss ([@B15]). The innate immune system has received much interest as having a defined role in the progression and/or etiology of MS ([@B51]; [@B19]). Innate immunity is regulated by complex mechanisms involving pattern-recognition receptors (PRRs) that recognize molecular signatures of microbes. Intracellular signaling triggered by PRRs leads to transcriptional expression of inflammatory mediators that coordinate the elimination of pathogens ([@B1]). If left unchecked, or not tightly regulated, dysregulation of this system can lead to conditions such as sepsis and autoimmunity ([@B42]).

Toll-like receptors (TLRs) belong to the family of signaling PRRs ([@B32]) that initiate innate immune reactions by activating transcription factors such as nuclear factor (NF)-κB, in addition to inducing the expression of interferons (IFNs) and cytokines. Thus far, 12 functional TLRs have been identified in mice, and 10 in humans ([@B54]; [@B36]). TLRs are localized in endosomal compartments (including TLR3, TLR7, TLR8, TLR9), or are cell membrane-bound (as with all other TLRs; [@B54]), and couple to specific signaling cascades, inducing gene transcription and controlling immune processes, with this specificity reliant on the TLR adaptor proteins recruited ([@B54]). All TLRs (with the exception of TLR3), recruit the adaptor myeloid differentiation factor 88 (MyD88; [@B45]). TLR3 (and TLR4) induces MyD88-independent signaling to couple to NF-κB via Toll-Interleukin-1 Receptor (TIR)-domain-containing adaptor-inducing IFN-β (TRIF) protein. TLRs are key players in CNS diseases, and with respect to MS, key roles of TLRs have been shown in murine models of MS ([@B66]), while the expression of TLRs characterized on immune cells and CNS glia and neurons ([@B50]).

Gamma amino butyric acid (GABA) is the major inhibitory amino acid neurotransmitter in the brain ([@B14]). GABA exerts its effects through the ionotropic receptors, GABA~A~/GABA~A-ρ~ and the metabotropic receptor GABA~B~ ([@B8]; [@B10]; [@B58]), and GABA receptor transcripts are present in neurons, glia ([@B41]; [@B69]), and immune cells ([@B6]). There is a growing body of evidence pointing to the key role of GABA receptors in neuroinflammation ([@B71]; [@B67]), and recent reports has identified that modulation of the GABAergic system occurs in MS ([@B29]; [@B11]). Indeed, GABA insufficiency has been identified in MS patients ([@B17]), while intrathecal administration of the GABA~B~ receptor agonist, baclofen, is used as a treatment strategy to control spasticity in patients with MS ([@B27]). Furthermore, enhancing endogenous GABA via administration of the GABA-degrading enzyme GABA-transaminase (GABA-T), has been shown to be protective in an experimental autoimmune encephalomyelitis (EAE) mouse model ([@B11]), indicating that increasing endogenous GABA also has therapeutic potential in the murine model of MS. In support of these *in vivo* findings, *in vitro* studies have shown that baclofen reduces TLR4-induced release of pro-inflammatory cytokines from primary murine microglia ([@B39]), indicating that cross talk may exist between the GABAergic and TLR systems, with relevance to inflammatory signaling events.

GABA~B~ receptors are metabotropic G~i~/G~o~-coupled receptors ([@B56]) which are distributed throughout the CNS and periphery ([@B55]; [@B31]). GABA~B~ receptors can function to regulate ion channels (activate K^+^ and inhibit Ca^2+^ channels) and cellular signaling (adenylate cyclase, MAPK; [@B37]; [@B33]), limit the release of neurotransmitters (GABA, glutamate; [@B58]; [@B26]), and dampen depolarisation induced by excitatory neurotransmitters. GABA~B~ receptors are implicated in a variety of neurodegenerative, neuroinflammatory, and pathophysiological disorders including depression, spasticity, pain, and schizophrenia ([@B62]; [@B7]; [@B25]). Given previous reports linking TLR's and the GABA~B~ receptor subtype with neuroinflammation, particularly with relevance to MS pathogenesis, we sought to explore the impact of baclofen (the GABA~B~ receptor agonist) on TLR3 and TLR4-induced inflammatory signaling both centrally and in the periphery, using murine glial cells and human peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals and newly-diagnosed patients with the relapsing-remitting (RR) form of MS patients. This study identifies baclofen as a differential regulator of TLR3 and TLR4 signaling in glia and immune cells, and offers insight on the role of baclofen in regulating the innate immune response in cellular pathology associated with MS.

Materials and Methods {#s1}
=====================

Preparation of Primary Mixed Glial Cultures and Treatments
----------------------------------------------------------

Primary mixed glia were prepared from the whole brain of 1-day-old C57/BL6 mice and plated (at 5 × 10^5^ cells/ml) as previously described ([@B20]). All experiments were performed under a license issued by the Health Products Regulatory Authority (Ireland) and in accordance with the European Directive 86/609/EEC and the guidelines laid down by the Animal Experimentation Ethics Committee of University College Cork. After 14 days in culture, mixed glia were treated with the TLR4 ligand LPS (100 ng/ml; Sigma--Aldrich, UK), the TLR3 ligand Poly(I:C) (10 μg/ml; InvivoGen, France) or vehicle (sterile H~2~O) for timepoints ranging from 10 min--24 h. In a second series of experiments, mixed glia were exposed to the GABA~B~ agonist baclofen (10, 30, and 100 μM; Sigma--Aldrich, Germany) for 30 min prior to LPS (100 ng/ml; 30 min and 24 h) or Poly(I:C) (10 μg/ml; 6 h and 24 h) exposure.

Patients and Blood Samples
--------------------------

Healthy donors and RR-MS patients attending outpatient clinics at the Mercy University Hospital, Cork, were recruited for this study. Written informed consent was obtained from each participant and the study received ethical approval from the Clinical Research Ethics committee of the Cork Teaching Hospitals (CREC). Patient recruitment into the study was via a Senior Consultant Neurologist and patients had to meet the revised MacDonald diagnostic criteria for clinically defined MS ([@B59]) including patient history, clinical signs and symptoms, physical examination, and adjunctive diagnostic tools including MRI. The Disability Status Scale scores were taken using the Expanded Disability Status Scale (EDSS) by a Senior Consultant Neurologist in an outpatient clinic. All confirmed MS patients had a RR form of MS as defined by the revised McDonald criteria. Disease severity was scored at time of collection using the [@B40] EDSS. Patients with RR-MS were clinically stable and naïve to disease modifying therapies including IFN-β, glatiramer acetate, fingolimod, teriflunomide, dimethyl fumarate, natalizumab, and alemtuzumab. PBMCs were collected from venous blood of healthy controls participants (mean age 30.3 ± 1.4 years; *n* = 16) and RR-MS patients (mean age 39.3 ± 3.2 years; *n* = 8) by way of venipuncture as previously described ([@B22]). Details of the patient demographics are presented in **Figure [3A](#F3){ref-type="fig"}**. Human PBMCs were prepared from heparinized venous whole blood samples (50 ml per donor) from individuals by density separation over Lymphoprep^TM^ (Axis-Shield, Norway). PBMCs were plated (1 × 10^6^ cells/ml) on 24-well plates prior to treatment. Plasma samples were separated following centrifugation, aliquoted, and stored at -80°C for subsequent analysis via ELISA.

Cytokine Analysis in Culture Supernatants
-----------------------------------------

Mixed glia (5 × 10^5^ cells/ml) and PBMCs (1 × 10^6^ cells/ml) were seeded overnight in 24-well plates. Cells were incubated with LPS (100 ng/ml) or Poly(I:C) (10 μg/ml) for timepoints ranging from 10 min--24 h. Mixed glia/PBMCs were also pre-exposed (30 min) to baclofen (10, 30, and 100 μM) prior to LPS (100 ng/ml; 24 h) or Poly(I:C) (10 μg/ml; 24 h) exposure. Supernatants were assayed for tumor necrosis factor-α (TNF-α) and IL-8 concentration by ELISA according to manufacturer's instructions (Duoset, R&D Systems, Abingdon, UK).

Quantitative Real-Time PCR
--------------------------

RNA was extracted from PBMCs (untreated) using a NucleoSpin^®^ RNAII isolation kit (Macherey-Nagel Inc., Geschäftsführer, Germany). The concentration of RNA was determined using a UV/V is spectrophotometer. cDNA synthesis was performed on 1 μg RNA using a High Capacity cDNA RT Kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufacturer's instructions. Equal amounts of cDNA were used for RT-PCR amplification. Real-time PCR primers were delivered as "Taqman^®^ Gene Expression Assays" containing forward and reverse primers, and a FAM-labeled MGB Taqman probe for the target gene (Applied Biosystems). GABA~B1~ primers were used to assess the expression of the target gene (Taqman Gene Expression Assay no. Hs00181306_m1). cDNA (1:4 dilution) was prepared and real-time PCR performed using Applied Biosystems 7300 Real-time PCR System. cDNA was mixed with qPCR^TM^ Mastermix Plus (Applied Biosystems) and the respective gene assay in a 25 μl volume (10 μl of diluted cDNA, 12.5 μl Taqman^®^ Universal PCR Mastermix, 1.25 μl target primer and 1.25 μl 18S). Eukaryotic 18S rRNA was used as an endogenous control and expression was conducted using a gene expression assay containing forward and reverse primers and a VIC-labeled MGB Taqman probe (\#4319413E; Applied Biosystems, USA). Samples were run in duplicate and 40 cycles were run as follows: 10 min at 95°C and for each cycle, 15 s at 95°C and 1 min at 60°C. Gene expression was calculated relative to the endogenous control and analysis was performed using the 2^-ΔΔCT^ method. In all experiments no change in relative 18S rRNA expression between treatment groups was observed.

TNF-α and IL-8 Measurement in Plasma
------------------------------------

Plasma samples from healthy donors and RR-MS patients were analyzed for concentrations of TNF-α and IL-8 by ELISA (Duoset, R&D Systems, UK) according to manufacturer's instructions.

Immunocytochemistry
-------------------

Mixed glia (5 × 10^5^ cells/ml) and PBMCs (1 × 10^6^ cells/ml) were seeded overnight on 13-mm diameter coverslips coated with poly-l-lysine (Sigma--Aldrich) and grown for 24 h. Cells were incubated with LPS (100 ng/ml) or Poly(I:C) (10 μg/ml) for timepoints ranging from 10 min--24 h. Mixed glia/PBMCs were also pre-exposed (30 min) to baclofen (10, 30 and 100 μM) prior to LPS (100 ng/ml; 30 min) or Poly(I:C) (10 μg/ml; 6 h) exposure. Cells were then fixed in ice-cold methanol for 10 min, permeabilized with 0.2% Triton X-100 (Thermo Fisher Scientific, Waltham, IL, USA) in PBS for 10 min at room temperature and blocked with 10% goat serum (Vector Laboratories, Peterborough, UK) for 2 h. Cells were treated overnight at 4°C with rabbit polyclonal NF-κB p65 antibody (1:200 in 5% goat serum; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Cells were then washed and incubated with goat anti-rabbit Alexa488 secondary antibody (1:1000 in 5% goat serum; Invitrogen, Dublin, Ireland) and 4′,6-diamidino-2-phenylindole (DAPI; 1.5 μg/ml) in PBS, washed, and mounted (Vectashield; Vector Laboratories). Cells were imaged using an Olympus IX70 inverted microscope. The fluorescence intensity in the nucleus of individual cells stained for NF-κB p65 was measured using the Image J analysis software (Rasband,WJ, <http://rsb.info.nih.gov/ij/>). The relative fluorescence intensity was calculated as the intensity after subtraction of the background noise. For each treatment, six coverslips were stained and five fields of view were captured per coverslip. Negative control experiments were performed by replacing the primary antibody with PBS and using equal gain settings during acquisition and analysis.

Statistical Analysis
--------------------

Data were analyzed using one-way or two-way analysis of variance (ANOVA) as appropriate. When analysis by ANOVA indicated significance (*P* \< 0.05), the *post hoc* Student Newman--Keuls test was used. Correlation tests were performed using two-tailed Spearman (non-parametric) correlation coefficient. Data are expressed as means ± SEs of the mean (SEM).

Results
=======

TLR4 Activation Time-Dependently Increases Nuclear NF-κB p65 Expression and TNF-α Release in Mixed Glia
-------------------------------------------------------------------------------------------------------

TLR4 and TLR3 were initially targeted given their involvement in EAE progression ([@B66]) and evidence that their expression is dysregulated in MS lesions ([@B9]). To initially characterize the impact of TLR4 stimulation on pro-inflammatory signaling in primary murine mixed glial cells, we temporally assessed the impact of LPS on the distribution of the NF-κB p65 subunit in response to LPS treatment. Firstly, mixed glia were stimulated with LPS for various timepoints ranging from 10 min--24 h, and the localization of endogenous p65 was assessed by immunofluorescence (**Figures [1A,B](#F1){ref-type="fig"}**). In vehicle-treated glial cells, p65 is predominantly cytoplasmic, as evidenced by the detection of 488-conjugated immunocomplexes outside of the DAPI-stained regions (**Figure [1B](#F1){ref-type="fig"}**). Stimulation of glia with LPS time-dependently promoted the accumulation of p65 in the nucleus, peaking at 30 min and 1 h post-LPS exposure (**Figures [1A,B](#F1){ref-type="fig"}**). We next characterized the impact of TLR4 activation on TNF-α protein production in primary mixed glia. LPS time-dependently enhanced TNF-α expression in primary murine mixed glial cells, with mean maximal stimulatory effects on protein expression observed at 6--24 h (**Figure [1C](#F1){ref-type="fig"}**), indicating that TLR4 stimulation promotes inflammatory signaling in primary mouse glial cells in our culture system.

![**TLR4 and TLR3 stimulation promotes NF-κB p65 distribution to the nucleus and pro-inflammatory TNF-α expression in primary mixed glial cell cultures. (A,D)** The relative fluorescence intensity (corrected total cell fluorescence; CTCF) of nuclear NF-κB p65 subunit was determined using Image J to assess the subcellular localization of p65 in mixed glial cultures following exposure to **(A)** LPS and **(D)** poly(I:C) for the indicated time periods. **(B,E)** Immunofluorescent images assessing the subcellular localization of p65 in mixed glial cultures following exposure to **(B)** LPS and **(E)** poly(I:C) for the indicated time periods. Nuclei were stained with DAPI, and images obtained using an Olympus IX70 inverted microscope equipped with the appropriate filter sets. Data are presented as the mean ± S.E.M and are representative of six animals. Scale bar = 20μm. Mixed glial cells were incubated with **(C)** LPS and **(F)** poly(I:C) (timepoints from 10 min--24 h) and supernatants were analyzed for TNF-α production using ELISA. Data are presented as the mean ± SEM of triplicate determinations and are representative of six animals. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 compared with vehicle-treated cells.](fncel-09-00284-g001){#F1}

TLR3 Activation Enhances Nuclear NF-κB p65 Expression and TNF-α Release in Mixed Glia
-------------------------------------------------------------------------------------

To assess the impact of TLR3 stimulation on inflammatory signaling events in mixed glial cells, we next assessed the effect of poly(I:C) exposure on the distribution of the NF-κB p65 subunit. Primary murine glial cells were incubated with poly(I:C) for timepoints ranging from 10 min--24 h, and the localization of the p65 subunit assessed by immunofluorescence (**Figures [1D,E](#F1){ref-type="fig"}**). TLR3 stimulation time-dependently promoted the accumulation of NF-κB in the nucleus, peaking at 6 and 8 h post-poly(I:C) exposure (**Figures [1D,E](#F1){ref-type="fig"}**). This temporal profile differed in response to TLR4 stimulation, where maximal sequestration of NF-κB p65 was observed at 30 min and 1 h post-LPS treatment (**Figure [1A](#F1){ref-type="fig"}**). Poly(I:C) significantly enhanced TNF-α expression in mixed glial cells, with mean maximal stimulatory effects on protein expression observed at 24 h (**Figure [1F](#F1){ref-type="fig"}**). This indicates that TLR3 and TLR4 activation in primary glia robustly enhances pro-inflammatory signaling in primary murine glial cells.

Effect of the GABA~B~ Receptor Agonist Baclofen on TLR4-Induced NF-κB-p65 Nuclear Expression and Pro-Inflammatory Cytokine Release in Mixed Glia
------------------------------------------------------------------------------------------------------------------------------------------------

We next examined the impact of the GABA~B~ agonist baclofen on TLR4-induced inflammatory signaling events in primary mixed glia. Glial cultures were pre-treated (30 min) with baclofen (10, 30, and 100 μM) prior to LPS exposure (30 min) and nuclear expression of NF-κB-p65 measured by fluorescence microscopy (**Figures [2A,B](#F2){ref-type="fig"}**). Stimulation of glia with LPS promoted the accumulation of p65 in the nucleus (**Figure [2A](#F2){ref-type="fig"}**). Pre-exposure to baclofen (at 30 μM) significantly attenuated the LPS-induced accumulation of p65 in the nucleus, while pre-incubation of glia with the GABA~B~ agonist at concentrations of 10 μM (*p* = 0.09) and 100 μM (*p* = 0.85), failed to significantly impact LPS-induced nuclear p65 sequestration (**Figures [2A,B](#F2){ref-type="fig"}**). Similarly, **Figure [2C](#F2){ref-type="fig"}** demonstrates that baclofen attenuated LPS-induced TNF-**α** production in glia at concentrations of 10 and 30 μM, although this did not reach statistical significance. These findings suggest that the proclivity of baclofen to impact TLR4 signaling in primary mixed glia is concentration dependent.

![**GABA~B~ receptor activation modulates TLR4- and TLR3-induced NF-κB-p65 nuclear expression and TNF-α expression release in glia. (A,D)** CTCF of nuclear NF-κB p65 subunit in mixed glial cultures following exposure to **(A)** LPS (30 min) and **(D)** poly(I:C) (6 h) in the absence and presence of baclofen (10, 30, and 100 μM). **(B,E)** Immunofluorescent images demonstrating the subcellular localization of p65 in glia following exposure to **(B)** LPS ± baclofen and **(E)** poly(I:C) ± baclofen. Nuclei were stained with DAPI, and images obtained using an Olympus IX70 inverted microscope equipped with the appropriate filter sets. Data are presented as the mean ± SEM and are representative of six animals. Scale bar = 20 μm. Mixed glial cells were pre-incubated with baclofen (10, 30, and 100 μM) prior to **(C)** LPS and **(F)** poly(I:C) (both at 24 h) and supernatants analyzed for TNF-α expression by ELISA. Data are presented as the mean ± SEM of triplicate determinations from six animals. ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 compared with vehicle-treated cells. \#*p* \< 0.05 compared to cells treated with LPS or Poly(I:C) in the absence of baclofen.](fncel-09-00284-g002){#F2}

GABA~B~ Receptor Activation Modulates TLR3-Induced NF-κB-p65 Nuclear Expression and TNF-α Expression in Glia
------------------------------------------------------------------------------------------------------------

Given that GABA~B~ activation modulates TLR4-induced signaling in glia, we next assessed the impact of baclofen on TLR3-induced inflammatory signaling in glial cells. Pre-incubation of glia with baclofen dose-dependently attenuated poly(I:C)-induced nuclear sequestration (at 6 h) of NF-κB, reaching significance at 100 μM (**Figures [2D,E](#F2){ref-type="fig"}**). Baclofen reduced poly(I:C)-induced TNF-**α** production in glia at concentrations of 100 μM, although this did not reach statistical significance (**Figure [2F](#F2){ref-type="fig"}**). These findings suggest that GABA~B~ activation regulates TLR3 signaling to NF-κB in glia in a concentration-dependent manner.

Demographic Data of Human Participants
--------------------------------------

A total of 24 subjects were assessed consisting of healthy control participants (*n* = 16) and newly diagnosed RR-MS patients (*n* = 8). All RR-MS patients were drug naïve at the time of inclusion. Mean disease duration in the RR-MS cohort was 1.2 ± 0.3 years and subjects had mild to moderate disability as reflected by EDSS scores of 2.6 ± 0.4 on average. The mean age of the 24 participants who enrolled in the investigation was 33.1 ± 7.8 years (range 23--40 years in control cohort; range 31--54 years in RR-MS cohort) and 46% of the sample was female. The overall demographics of the participants are reported in **Figure [3A](#F3){ref-type="fig"}**.

![**Demographic and clinical characteristics of MS patients and control subjects included in the study. (A)** Demographics of healthy control participants and RR-MS patients. Expanded Disability Status Scale (EDSS). **(B)** Plasma levels of IL-8 and TNF-α in control (*n* = 16) and MS (*n* = 8) cohort. Detection rates and mean plasma expression values of IL-8 and TNF-α are summarized. **(C,D)** Correlation between IL-8/TNF-α plasma levels and age of study participants. Correlation plots demonstrating **(C)** IL-8 and **(D)** TNF-α plotted against subject age. No correlation was observed between age in control and MS groups analyzed (two-tailed Spearman non-parametric correlation coefficient, correlation *r*-values, and significance *p*-values, are indicated in the graphs). Levels of TNF-α and IL-8 in **(E)** healthy control participants and **(F)** MS patients in plasma obtained from male (*n* = 13) and female (*n* = 11) participants. **(G)** Peripheral blood mononuclear cells (PBMCs) isolated from healthy subjects and newly diagnosed RR-MS patients were assessed for GABA~B~ mRNA expression, cDNA generated and assayed by quantitative real-time PCR for levels of GABAB~1~ mRNA. Data are presented as the mean ± SEM of triplicate determinations. ^∗^*p* \< 0.05 compared with male control subjects **(E)**. ^∗^*p* \< 0.05 compared with all control subjects **(G)**.](fncel-09-00284-g003){#F3}

Cytokine and Chemokine Analysis in Human Plasma
-----------------------------------------------

To determine if RR-MS is associated with alterations in peripheral inflammatory signature, we initially assessed plasma levels of the inflammatory chemokine IL-8 and cytokine TNF-α in plasma from control and RR-MS groups. No significant difference in plasma IL-8 (*p* = 0.94) and TNF-α (*p* = 0.28) concentration was found between groups (**Figure [3B](#F3){ref-type="fig"}**). Detection rates and mean values of plasma TNF-α and IL-8 are summarized in **Figure [3B](#F3){ref-type="fig"}**. In addition, no clear correlation between the levels of plasma cytokines and participant age was determined in either RR-MS patient or control groups (two-tailed Spearman non-parametric correlation coefficient; **Figures [3C,D](#F3){ref-type="fig"}**), indicating that participant age had no impact on peripheral cytokine/chemokine expression. We next assessed the impact of gender on plasma cytokine and chemokine levels. Interestingly, compared to male control subjects, the expression levels of TNF-α and IL-8 were significantly reduced in female control subjects (**Figure [3E](#F3){ref-type="fig"}**). No significant difference was determined between males vs. females in the RR-MS cohort (**Figure [3F](#F3){ref-type="fig"}**). This data indicates that the level of cytokine/chemokine expression in healthy individuals is higher in males than females, but that this gender difference is not apparent in the RR-MS cohort.

GABA~B~ Expression in Human PBMCs
---------------------------------

To determine the expression profile of the metabotropic receptor GABA~B~ in human PBMCs, and whether this profile was altered in disease, we assessed the expression of GABA~B1~ subunit in PBMCs isolated from healthy volunteers and RR-MS patients. Detectable levels of the GABA~B1~ subunit was determined in human PBMCs, with RR-MS associated with a reduction (twofold) in endogenous GABA~B1~ expression when compared to PBMCs isolated from healthy subjects (**Figure [3G](#F3){ref-type="fig"}**). This indicates that downregulation of GABA~B~ receptors occurs in PBMCs isolated from newly diagnosed RR-MS patients, when compared to immune cells from healthy subjects.

Effect of TLR3 and TLR4 Stimulation on PBMCs Isolated from Control and RR-MS Cohorts
------------------------------------------------------------------------------------

Given the defined role of TLR3 and TLR4 in EAE progression ([@B66]), in addition to evidence that their expression is up-regulated in MS lesions ([@B9]), we next set out to assess the impact of TLR3 and TLR4 stimulation on inflammatory responses of immune cells isolated from control and RR-MS patients. Firstly, supernatants from unstimulated PBMCs isolated from RR-MS patients displayed enhanced TNF-α (**Figures [4A,C](#F4){ref-type="fig"}**) and IL-8 (**Figures [4B,D](#F4){ref-type="fig"}**) expression, when compared to PBMCs from healthy subjects, indicating the RR-MS patient PBMCs display an enhanced endogenous inflammatory signature. LPS enhanced TNF-α production in PBMCs from both groups (**Figure [4A](#F4){ref-type="fig"}**), and importantly the production of TNF-α was exacerbated in PBMCs prepared from the RR-MS group, compared with the control cohort (**Figure [4A](#F4){ref-type="fig"}**). In terms of IL-8 expression, two-way ANOVA revealed a significant influence of disease status on IL-8 levels \[*F*~(1,30)~ = 4.773, *p* = 0.0369\], but no significant influence of TLR4 stimulation on overall variation \[*F*~(2,30)~ = 0.7174, *p* = 0.4962\] (**Figure [4B](#F4){ref-type="fig"}**). However, *post hoc* analysis revealed a trend toward a statistically significant increase in IL-8 release following LPS treatment in PBMCs isolated from healthy controls (*p* = 0.0612), but not in RR-MS patients. Interestingly, PBMCs isolated from healthy subjects and RR-MS patients were unresponsive to poly(I⋅C) stimulation, both in terms of TNF-α and IL-8 production (**Figures [4C,D](#F4){ref-type="fig"}**), indicating that PBMCs from control individuals and RR-MS patients are refractory to TLR3 stimulation, in terms of TNF-α and IL-8 signaling.

![**Peripheral blood mononuclear cells from RR-MS patients display enhanced inflammatory signaling.** PBMCs prepared from healthy subjects and MS patients were seeded into 24-well plates and treated with vehicle, LPS (100 ng/ml) or poly(I⋅C) (10 μg/ml) for 24 h. Supernatants were analyzed for TNF-α **(A,C)** and IL-8 **(B,D)** production using ELISA. Data are presented as the mean ± SEM of triplicate determinations. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 compared with vehicle-treated PBMCs from healthy subjects. ^\#\#\#^*p* \< 0.001 compared with vehicle-treated cells from MS patients.](fncel-09-00284-g004){#F4}

Baclofen Attenuates TLR4-Induced TNF-α Cytokine Release in Human PBMCs Isolated from Healthy, but not RR-MS, Subjects
---------------------------------------------------------------------------------------------------------------------

Given that GABA~B~ activation modulates TLR4-induced signaling in primary mixed glia (**Figure [2](#F2){ref-type="fig"}**), and that TLR4 stimulation enhances TNF-α signaling in PBMCs from control and RR-MS patients (**Figure [4](#F4){ref-type="fig"}**), we next assessed the proclivity of baclofen to modulate TLR4-induced TNF-α release in PBMCs isolated from healthy subjects and RR-MS patients. PBMCs from healthy subjects (**Figure [5A](#F5){ref-type="fig"}**) and RR-MS patients (**Figure [5B](#F5){ref-type="fig"}**) were pre-treated (30 min) with baclofen (10, 30, and 100 μM) prior to LPS exposure (24 h) and TNF-α expression assessed. PBMCs isolated from healthy subjects were responsive to LPS with an increase in TNF-α release observed, whereas baclofen modestly attenuated this (**Figure [5A](#F5){ref-type="fig"}**). In contrast, pre-exposure (30 min) to baclofen prior to LPS exposure (24 h) failed to significantly impact TLR4-induced TNF-α expression in PBMCs from RR-MS patients at each dose tested (**Figure [5B](#F5){ref-type="fig"}**). Importantly, this indicates a differential sensitivity of cells from healthy and RR-MS subjects in terms of the ability of baclofen to modulate TLR-induced inflammatory signaling, which may have implications in terms of the design of GABA~B~ receptor therapeutics to treat neuroinflammatory disorders including MS.

![**GABA~B~ activation attenuates TLR4-induced TNF-α production in PBMCs from healthy, but not MS, subjects.** PBMCs isolated from **(A)** healthy subjects and **(B)** MS patients were seeded in 24-well plates and pre-treated with baclofen (10, 30, and 100 μM) in the absence and presence of LPS (100 ng/ml) for 24 h. Supernatants were analyzed for TNF-α production using ELISA. Data are presented as the mean ± SEM of triplicate determinations. ^∗∗^*p* \< 0.01 and ^∗∗∗^*p* \< 0.001 compared with vehicle-treated cells. ^\#\#^*p* \< 0.01 and ^\#\#\#^*p* \< 0.001 compared to cells treated with LPS in the absence of baclofen.](fncel-09-00284-g005){#F5}

Discussion
==========

Understanding the mechanisms underlying neuroinflammatory processes in MS may pave the way to novel therapeutic strategies. Data herein demonstrate that the GABA~B~ receptor agonist baclofen has the proclivity to differentially target TLR4 and TLR3 inflammatory signaling events both in CNS glial cells, and in peripheral immune cells. Baclofen reduced TLR3/4-induced nuclear NF-κB and TNF-α (albeit modestly) expression in glial cells, with distinct dose-dependency identified for these effects. GABA~B~ receptor activation attenuated TLR4-induced TNF-α expression in PBMCs isolated from healthy individuals, while baclofen had no impact on TLR4 signaling in RR-MS patient PBMCs. Furthermore, PBMCs from RR-MS patients expressed lower levels of the GABA~B~ receptor mRNA. Significantly, we also determined that immune cells from the RR-MS patient group displayed hypersensitivity to LPS exposure in terms of TNF-α expression.

TLR family members are expressed in cells of the CNS ([@B21]; [@B49]) and TLR ligands regulate CNS inflammation ([@B42]). We initially targeted TLR3 and TLR4 signaling given the role of these receptors in neuroinflammatory events linked with MS ([@B9]; [@B66]). Both NF-κB activation and pro-inflammatory cytokine expression are known downstream signaling events following ligation of TLR3 and TLR4 ([@B47]), and signaling via both cascades is perturbed following TLR3 ([@B12]) and TLR4 ([@B18]) knockout. We examined the ability of LPS and poly(I:C) to couple to TLR4 and TLR3 inflammatory signaling in primary glia, respectively. Data presented herein indicate that LPS and poly(I:C) enhanced NF-κB activation and TNF-α cytokine expression in glia, with the kinetics of this response mirroring data described elsewhere ([@B57]; [@B30]).

This study highlights the anti-inflammatory potential of baclofen in glial cells, by virtue of its inhibitory effects on the NF-κB-TNF-α pathway induced by TLR3/4 activation. This is consistent with data elsewhere indicating that baclofen reduces LPS-induced production of IL-6/IL-12 in mouse microglia ([@B39]), and reduces phospho-p65-NF-κB and IL-6/TNF-α expression in human astrocytes and microglial cells stimulated with IFN-γ/LPS ([@B41]). GABA~B~ receptors are expressed on astrocytes and microglia ([@B13]), and evidence indicates that glial GABA~B~ receptors are functional ([@B39]; [@B53]). Given the expression and functional activity of GABA~B~ receptors on glia, alongside evidence that baclofen negatively regulates TLR3/4-induced inflammatory signaling, it is likely that GABA~B~ receptors play an integral role in the course of neuroinflammation by targeting glia. The ability of baclofen to target TLR3/4-induced inflammatory signaling in glia *in vitro* may contribute to an anti-inflammatory efficacy *in vivo*, and this will be the focus of further studies.

Interestingly, different effects of GABA~B~ receptor modulation on the immune system have been indicated, suggesting that GABA is a regulator of immune cell activity and inflammation. Indeed, GABA receptors have been identified on neutrophils, macrophages, dendritic cells, and T-cells ([@B60]; [@B34]), and cells of the immune system possess the metabolic machinery for the synthesis of GABA ([@B5]). Given the evidence that GABA is a neuroimmune modulator, alongside our findings that baclofen modulates TLR-induced inflammatory signaling in central glial cells, we next assessed the impact of baclofen on TLR signaling in peripheral immune cells. Firstly, our findings indicate that TLR4 activation promotes TNF-α and IL-8 cytokine expression in human PBMCs, and these findings are consistent with data elsewhere ([@B35]; [@B22]). Importantly, data presented herein indicate an anti-inflammatory propensity of baclofen in human immune cells, demonstrating that baclofen blunts LPS-induced TNF-α expression in peripheral immune cells from healthy subjects. This finding is in line with data demonstrating that exposure of human PBMCs to baclofen ameliorates phytohemagglutinin-induced TNF-α release ([@B23]). A significant finding here is that this is the first direct evidence that baclofen can target TLR signaling in human PBMCs, and hence has relevance across a range of neuroimmune disorders.

Our results identify that PBMCs isolated from healthy subjects were responsive to baclofen, with a significant, albeit moderate, decrease in LPS-induced TNF-α expression observed following baclofen treatment. In contrast, baclofen failed to regulate TLR4-induced TNF-α expression in PBMCs from RR-MS subjects. This is significant as intrathecal administration of baclofen can be used to treat spasticity in MS, in addition to spinal cord injury, cerebral palsy, and acquired brain injury ([@B27]). Furthermore, there is evidence of a loss of GABAergic neurons at lesion sites in post-mortem MS brain ([@B61]). The differential sensitivity of cells from healthy and RR-MS subjects to baclofen indicates that MS drives a desensitizing signal in terms of GABA~B~ receptor function. Indeed, our findings indicate that downregulation of GABA~B~ receptors occurs in PBMCs in newly diagnosed RR-MS patients, which may govern the differential sensitivity to baclofen exposure seen in healthy and MS patient cells. In support of this, the level of GABA is reduced in the blood serum of patients with MS as compared to the controls ([@B17]). In addition, baclofen treatment has been shown to reduce GABA~B~ receptor density in rat spinal cord ([@B38]), which may be postulated as a molecular mechanism for development of tolerance. It is especially interesting to note that treatment failure has been shown with baclofen in MS patients ([@B65]), and the inability of baclofen to target TLR4-induced pro-inflammatory cytokine production might contribute to these effects.

Whether the effects of baclofen identified in the present and other studies are a direct result of its action at the GABA~B~ receptor is not yet entirely clear, particularly given the recent discovery that baclofen, and several GABA~B~ receptor antagonists, are allosteric modulators of CXCR4, a chemokine receptor involved in neuroimmune crosstalk ([@B28]). Indeed, determining whether the effects of baclofen that were observed in this study are specifically due to its action at the GABA~B~ receptor rather than at CXCR4 will be the focus of future studies. Such studies will be challenging because several GABA~B~ receptor antagonists also act as allosteric modulators of CXCR4 ([@B28]). Future studies aimed at identifying GABA~B~ receptor antagonists that do not affect CXCR4 activity will be required in order to address this question directly. Nevertheless, since baclofen and some GABA~B~ receptor antagonists exert the same effects on CXCR4 activity ([@B28]), then it would be expected that prevention of the effects of baclofen by a GABA~B~ receptor antagonist would be independent of CXCR4 activity (since both baclofen and the GABA~B~ receptor antagonists behave as CXCR4 antagonists). Alternatively, experiments could examine the effects of baclofen under conditions whereby CXCR4 expression or activity is altered, however, such experiments might be complicated by the modulation of inflammatory mediators by CXCR4 itself. Despite these limitations, there is accumulating evidence that many components of the GABA neurotransmitter system, including not only the GABA~B~ receptor but also the GABA~A~ receptor, can have anti-inflammatory effects ([@B64]; [@B6]; [@B41]).

The rationale behind the present study was to determine if baclofen could target TLR-induced signaling in RR-MS, particularly given the growing body of data indicating that the TLR system is a key player in MS pathogenesis ([@B51]; [@B19]). However, intrathecal administration of baclofen is used to manage spasticity in patients with a range of conditions including spinal cord injury, cerebral palsy and acquired brain injury in addition to MS, and hence in future studies it would be interesting to compare the effects of baclofen on the PBMCs of patients with other neurological conditions.

The concentrations of cytokines/chemokines are altered in MS ([@B68]), suggesting that cytokine/chemokine signatures may indicate disease progression in patient groups ([@B52]). Given that evidence indicates that TNF-α ([@B63]) and IL-8 ([@B43]) are higher in serum of patients with MS, we examined the relative expression of TNF-α and IL-8 in plasma isolated from newly diagnosed RR-MS patients. Our analysis revealed no difference in plasma IL-8/TNF-α between control and RR-MS groups. Systemic inflammation in MS is strongly associated with periods of intense relapse ([@B16]), hence it is plausible that alterations in peripheral cytokines in MS may be phase dependent. In support of this, [@B46] indicate that MS patients with EDSS measurements in the range comparable to the RR-MS cohort assessed in present study demonstrate no alteration in plasma TNF-α when compared to healthy subjects ([@B46]).

Neuroinflammatory changes develop with age, with defects in the immune system identified in elderly individuals ([@B2]). In addition, an increased plasma level of pro-inflammatory cytokines has been demonstrated in elderly, compared to young, individuals ([@B24]). Our findings indicate no clear correlation between the levels of plasma cytokine/chemokine and participant age in either RR-MS or control groups, indicating that the age of subjects did not impact cytokine/chemokine profiles. Interestingly, compared to male control subjects, the expression levels of TNF-α and IL-8 were significantly reduced in female control subjects. This indicates that particular expression profiles of cytokines/chemokines may be gender specific, which is confirmed elsewhere ([@B4]).

Marked alterations in the expression profile of TLRs has been determined in MS lesions in human brain samples, in the brain samples from mice that have undergone EAE, and in CSF cells isolated from MS patients ([@B44]). With this in mind we investigated the effect of TLR4 and TLR3 stimulation on the pro-inflammatory cytokine and chemokine, TNF-α and IL-8. PBMCs without stimulation, as well as after stimulation with LPS, displayed increased production of TNF-α and IL-8 in the RR-MS sample cohort, when compared to the control group. These results suggest that immune cells from the RR-MS patient group have an enhanced endogenous inflammatory signature. In addition, RR-MS patient PBMCs displayed hypersensitivity to LPS exposure in terms of TNF-α expression. TLR4 expression is upregulated in CNS lesions in mice following EAE and in PBMCs from RR-MS and secondary progressive (SP) MS patients ([@B3]), which in support of our study, indicates that TLR4 signaling participates in an innate immune response that may shape the inflammatory response in both forms of MS. It is intriguing that the hypersensitivity of RR-MS patient cells to LPS is only relevant in the context of TNF-α induction, since LPS shows comparable efficacy in inducing IL-8 in cells from healthy and RR-MS patients. Hence, any form of TLR4 hypersensitivity that may exist in MS patient cells appears to be restricted to the pathway leading to TNF-α expression, and further studies will probe the intracellular signaling events in patient cells.

Our studies also probed the effects of TLR3 stimulation on TNF-α/IL-8 in PBMCs. Surprisingly, PBMCs isolated from healthy donors and RR-MS patients did not respond to TLR3 stimulation by enhancing TNF-α or IL-8 expression, suggesting that the TLR3 pathway leading to cytokine and chemokine expression may be desensitized in our participant cohorts. Indeed, we have previously demonstrated that the TLR3-IFN-β pathway is desensitized in MS patient PBMCs, suggesting that MS patients may be pre-sensitized to viral infection showing some form of TLR3 tolerance. However, the non-responsiveness of healthy donor PBMCs to poly(I⋅C) is in line ([@B70]) and in contrast ([@B48]) to findings elsewhere in studies which investigated freshly isolated PBMCs; differences in dose and timecourse for treatment regimen used with poly(I:C) in the present study may underlie the differences observed.

Although baclofen demonstrates therapeutic effects in MS, the mechanism(s) of action are poorly understood. We present evidence that the innate arm of the immune system is a target for baclofen anti-inflammatory action, and demonstrate that baclofen differentially targets TLR4 and TLR3 inflammatory signaling events both in primary murine glial cells and in PBMCs isolated from human blood samples. Baclofen can exert anti-inflammatory properties at specific doses, by down-regulating TLR-induced activation of NF-κB and induction of pro-inflammatory cytokines. Significantly, our findings also indicate that inflammatory signaling, and sensitivity to TLR4 stimulation, was enhanced in PBMCs of patients with RR-MS, highlighting that TLR4 may play a role at least in the RR form of MS pathogenesis. We targeted this particular patient cohort because they were newly-diagnosed and naïve to disease modifying therapies. However, investigating TLR functioning and its modulation by baclofen in patients with secondary chronic progressive MS would be an important future study. Overall, the present study provides novel insight into the cellular effects of targeting central and peripheral GABA~B~ receptors in the modulation of TLR functioning.
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